Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Talditercept alfa by Biohaven for Spinal Muscular Atrophy (SMA): Likelihood of Approval
Talditercept alfa is under clinical development by Biohaven and currently in Phase III for Spinal Muscular Atrophy (SMA). According to...
Talditercept alfa by Biohaven for Unspecified Metabolic Disorders: Likelihood of Approval
Talditercept alfa is under clinical development by Biohaven and currently in Phase I for Unspecified Metabolic Disorders. According to GlobalData,...
Talditercept alfa by Biohaven for Spinal Muscular Atrophy (SMA): Likelihood of Approval
Talditercept alfa is under clinical development by Biohaven and currently in Phase III for Spinal Muscular Atrophy (SMA). According to...